Prazosin

This classification denotes an antihypertensive agent and alpha-adrenergic blocking agent with the molecular formula C19H21N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XM03YJ541D, chemically known as 4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone but generally known as prazosin, which bears US NIH Compound Identifier 4893. European Medicines Agency schedules Prazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10011MIG. The term PRAZOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 24, No. 11 1970, List 10). World Health Organization schedules prazosin in its Anatomical Therapeutic Chemical (ATC) Classification. PRAZOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule prazosin under HS 29349990 and SITC 51579. As of Q4 2014, PRAZOSIN remains the US FDA Preferred Term for this commodity. Prazosin bears US NLM identifiers UMLS ID C0032912 and NCI Concept Code C767. SMILES: O=C(N1CCN(CC1)C1NC2C(C(N1)N)CC(OC)C(OC)C2)C1OCCC1.